Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Aún no traducido Aún no traducido
Categoría Estudio primario
Registro de estudiosClinicalTrials.gov
Año 2008

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
Cargando información sobre las referencias
Huntington\'s disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are available.Creatine monohydrate is considered a nutritional supplement. The purpose of CREST-E is to test whether high-dose creatine can slow the progressive functional decline that occurs in persons 18 years or older with early clinical features of HD. The long-term safety, tolerability and effectiveness of up to 40 grams daily creatine compared to placebo is studied. A variety of biological processes are assessed for markers of disease activity or progression and creatine effects. Up to 50 active research centers globally will enroll 650 subjects.
Epistemonikos ID: 54444fda25d9c400e9a496debe7653cc775d2ed5
First added on: Mar 30, 2022